• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

名字有何意义?无论我们如何称呼特发性肺纤维化(IPF),它的表现都是一样的。

What's in a name? That which we call IPF, by any other name would act the same.

机构信息

Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.

National Jewish Health, Denver, CO, USA.

出版信息

Eur Respir J. 2018 May 17;51(5). doi: 10.1183/13993003.00692-2018. Print 2018 May.

DOI:10.1183/13993003.00692-2018
PMID:29773608
Abstract

Idiopathic pulmonary fibrosis (IPF) remains a truly idiopathic fibrotic disease, with a modest genetic predilection and candidate triggers but no overall explanation for the development of disease in non-familial cases. Agreement on terminology has contributed to major clinical and translational advances since the millennium. It is likely that the entity currently captured by the term "IPF" will be radically reclassified over the next decade, either through "splitting" (into IPF subgroups responding selectively to individual disease-modifying agents) or through "lumping" of IPF with other forms of progressive fibrotic lung disease (with shared pathogenetic mechanisms and IPF-like disease behaviour). In this perspective, we summarise the clinical and pathogenetic justification for a focus on "the progressive fibrotic phenotype" in future clinical and translational research. By this means, we can hope to address the needs of non-IPF patients with inexorably progressive fibrotic disease, currently disenfranchised by lack of access to agents that are efficacious in IPF. In this regard, ongoing trials of anti-fibrotic therapies in non-IPF patients with progressive fibrosis may be highly influential. Future revision of IPF nomenclature may be warranted if there are major conceptual changes but without compelling justification, the benefits of renaming IPF are likely to be outweighed by the resulting confusion.

摘要

特发性肺纤维化(IPF)仍然是一种真正的特发性纤维化疾病,具有适度的遗传倾向和候选触发因素,但对于非家族性病例中疾病的发展尚无总体解释。自千禧年以来,术语的一致性促进了重大的临床和转化进展。目前被称为“IPF”的实体很可能在未来十年内通过“分裂”(分为对个别疾病修饰剂有选择性反应的 IPF 亚组)或通过将 IPF 与其他形式的进行性纤维化肺疾病“合并”(具有共同的发病机制和类似 IPF 的疾病行为)而得到彻底重新分类。从这个角度来看,我们总结了在未来的临床和转化研究中关注“进行性纤维化表型”的临床和发病机制依据。通过这种方式,我们可以希望满足目前因缺乏在 IPF 中有效的药物而被剥夺权利的进行性纤维化疾病非 IPF 患者的需求。在这方面,正在进行的针对进行性纤维化的非 IPF 患者的抗纤维化治疗试验可能具有重要影响。如果存在重大概念变化但没有令人信服的理由,则可能需要对 IPF 命名进行修订,但重新命名 IPF 的好处可能会被由此产生的混乱所抵消。

相似文献

1
What's in a name? That which we call IPF, by any other name would act the same.名字有何意义?无论我们如何称呼特发性肺纤维化(IPF),它的表现都是一样的。
Eur Respir J. 2018 May 17;51(5). doi: 10.1183/13993003.00692-2018. Print 2018 May.
2
An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?其他非特发性肺纤维化疾病中的特发性肺纤维化样疾病进程:如何预测、识别和管理?
Expert Rev Clin Immunol. 2021 Oct;17(10):1091-1101. doi: 10.1080/1744666X.2021.1968832. Epub 2021 Sep 1.
3
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.特发性肺纤维化合并轻度生理损害的疾病进展:来自澳大利亚特发性肺纤维化登记处的分析。
BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.
4
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?是时候改变了:特发性肺纤维化仍然是特发性的且仅纤维化吗?
Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9.
5
Inflammation and immunity in IPF pathogenesis and treatment.特发性肺纤维化发病机制和治疗中的炎症与免疫。
Respir Med. 2019 Feb;147:79-91. doi: 10.1016/j.rmed.2018.12.015. Epub 2019 Jan 9.
6
Lung cancer in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者的肺癌
Pulm Pharmacol Ther. 2017 Aug;45:1-10. doi: 10.1016/j.pupt.2017.03.016. Epub 2017 Apr 1.
7
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.抗纤维化药物尼达尼布和吡非尼酮治疗特发性肺纤维化(IPF)和非特发性肺纤维化(非 IPF)进展性肺纤维化的疗效:系统评价和荟萃分析。
BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1.
8
The Bleomycin Model of Pulmonary Fibrosis.博来霉素诱导的肺纤维化模型。
Methods Mol Biol. 2017;1627:27-42. doi: 10.1007/978-1-4939-7113-8_2.
9
Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.基于美国保险索赔数据的非特发性肺纤维化进行性纤维化性间质性肺疾病患者的医疗资源利用和费用。
Adv Ther. 2020 Jul;37(7):3292-3298. doi: 10.1007/s12325-020-01380-4. Epub 2020 May 21.
10
Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.气道巨噬细胞中胶原 1a1 的表达增加与纤维化 ILD 有关,并与 FVC 下降和死亡率增加相关。
Front Immunol. 2021 Nov 17;12:645548. doi: 10.3389/fimmu.2021.645548. eCollection 2021.

引用本文的文献

1
Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?纤维化间质性肺疾病抗纤维化治疗的启动:在证实疾病进展之前,时间是否紧迫?
Eur Respir Rev. 2025 Aug 6;34(177). doi: 10.1183/16000617.0023-2025. Print 2025 Jun.
2
Radiological Insights into UIP Pattern: A Comparison Between IPF and Non-IPF Patients.对普通型间质性肺炎模式的放射学见解:特发性肺纤维化与非特发性肺纤维化患者的比较
J Clin Med. 2025 Jun 12;14(12):4162. doi: 10.3390/jcm14124162.
3
Risk factors and prognostic indicators for progressive fibrosing interstitial lung disease: a deep learning-based CT quantification approach.
进行性纤维化间质性肺疾病的危险因素和预后指标:一种基于深度学习的CT量化方法。
Eur Radiol. 2025 Jun 17. doi: 10.1007/s00330-025-11714-x.
4
Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review.进行性肺纤维化的流行病学与预后:文献综述
Pulm Ther. 2025 Jun 16. doi: 10.1007/s41030-025-00302-5.
5
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis.与间质性肺疾病风险相关的吸入暴露:一项系统评价和荟萃分析。
Thorax. 2025 Jun 15. doi: 10.1136/thorax-2024-222306.
6
Blurred Boundaries: Rethinking Disease Classifications in Interstitial Lung Disease Using Molecular Signals.模糊的边界:利用分子信号重新思考间质性肺疾病的疾病分类
Am J Respir Crit Care Med. 2025 Aug;211(8):1333-1334. doi: 10.1164/rccm.202503-0720ED.
7
Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis.接受抗纤维化治疗的进行性非特发性肺纤维化患者的治疗效果、耐受性和生存率分析。
Ann Thorac Med. 2025 Apr-Jun;20(2):98-107. doi: 10.4103/atm.atm_213_24. Epub 2025 Mar 31.
8
Quantification of progressive pulmonary fibrosis by visual scoring of HRCT images: recommendations from Italian chest radiology experts.通过对高分辨率计算机断层扫描(HRCT)图像进行视觉评分对进行性肺纤维化进行定量分析:来自意大利胸部放射学专家的建议。
Radiol Med. 2025 Jun;130(6):965-977. doi: 10.1007/s11547-025-01985-1. Epub 2025 Apr 7.
9
Impact of the Human Leukocyte Antigen Complex on Idiopathic Pulmonary Fibrosis Development and Progression in the Sardinian Population.人类白细胞抗原复合体对撒丁岛人群特发性肺纤维化发生发展的影响
Int J Mol Sci. 2025 Mar 19;26(6):2760. doi: 10.3390/ijms26062760.
10
Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.木犀草素:探索其在肺部疾病中的治疗潜力和分子机制
Front Pharmacol. 2025 Feb 12;16:1535555. doi: 10.3389/fphar.2025.1535555. eCollection 2025.